Skip to main content
. 2020 Sep 30;72(11):e784–e790. doi: 10.1093/cid/ciaa1482

Table 4.

Summary of Covariates Significantly Associated With At Least 1 Adverse Pregnancy Outcome

Adjusted OR (95% CI)
Outcomea HBsAG positive vs negative Normal MUAC Noninfectious pregnancy complication vs none Infectious pregnancy complication vs none Twin gestation vs singleton Current smoker vs never/previous smoker HIV RNA < LLOQ vs ≥ LLOQ
Composite 1: fetal demise, PTD, LBW, or congenital anomaly 2.32 (1.01–5.30) .92 (.87–.96) 2.06 (1.34–3.17) .46 (.22–1.00) 14.43 (3.35–62.08)
Composite 2: fetal demise, PTD, LBW, or neonatal death (<28 days) .91 (.87–.96) 2.13 (1.39–3.28) 14.51 (3.38–62.29)
Composite 3: fetal demise, PTD, LBW, or early neonatal death (<7 days) .91 (.87–.96) 2.06 (1.33–3.19) 15.02 (3.50–64.38)
Perinatal death 1: fetal demise or neonatal death 6.21 (3.14–12.31)
Perinatal death 2: fetal demise or early neonatal death 6.76 (3.18–14.36) 6.01 (1.08–33.55)
LBW: <2500 grams at birth .88 (.83–.94) 19.09 (3.95–92.35) 3.18 (1.05–9.63)
PTD: <37 weeks gestation at delivery .93 (.87–.99) 1.90 (1.08–3.34) .29 (.09–.98) .56 (.32–.97)

The multivariable model includes study arm and the following covariates: maternal age at delivery, CD4 quartiles, HIV RNA < LLOQ, timing of ART initiation, HBsAG status, MUAC, IGRA status, twin versus singleton pregnancy, current smoker, noninfectious pregnancy complications, infectious pregnancy complications, and maternal hospitalization.

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HBsAG, hepatitis B surface antigen; HIV, human immunodeficiency virus; IGRA, interferon-gamma release assay; LBW, low birth weight; LLOQ, lower limit of quantification; MUAC, mid-upper arm circumference; OR, odds ratio; PTD, preterm delivery.

aEstimates are shown if P < .05.